Advertisement
Collaboration › Details
InflaRx–Cantor Fitzgerald: investor conference, 202409 supply service InflaRx to participate in Cantor Global Healthcare Conference
Period | 2024-09-18 | |
Region | New York, NY | |
Country | United States (USA) | |
Partner, 1st | InflaRx N.V. (Nasdaq Global Select Market: IFRX) | |
Group | InflaRx (Group) | |
Partner, 2nd | Cantor Fitzgerald & Co. | |
Group | Cantor Fitzgerald (Group) | |
Product | Cantor Global Healthcare Conference 2024 New York | |
Product 2 | anti-C5a antibody | |
Person | Medina, Jan (InflaRx 202402– Head of Investor Relations before Olink Proteomics) | |
InflaRx N.V.. (8/27/24). "Press Release: InflaRx Announces Participation in September Investor Events". Jena.
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will participate in two investor conferences in September 2024. Details are as follows:
H.C. Wainwright 26th Annual Global Investment Conference
September 9-11, 2024 in New York, NY
InflaRx’s on-demand virtual presentation for the conference will be available beginning on September 9th. InflaRx will also participate in one-on-one investor meetings in New York City on September 10th.
2024 Cantor Global Healthcare Conference
September 17-19, 2024 in New York, NY
InflaRx will conduct a fireside chat at the conference on September 18th at 9:45 am ET and will participate in one-on-one-investor meetings on the same day. A link to register for the fireside chat live stream and its replay is available here.
About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx is also developing INF904, an orally administered, small molecule inhibitor of the C5a receptor. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com.
InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).
Contacts:
InflaRx N.V.
Jan Medina, CFA
Vice President, Head of Investor Relations
Email:IR@inflarx.de
MC Services AG
Katja Arnold, Laurie Doyle, Dr. Regina Lutz
Email:inflarx@mc-services.eu
Europe: +49 89-210 2280
US: +1-339-832-0752
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading “Risk Factors” and “Cautionary statement regarding forward looking statements” in our periodic filings with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
Record changed: 2024-09-01 |
Advertisement
More documents for InflaRx (Group)
- [1] InflaRx N.V.. (8/27/24). "Press Release: InflaRx Announces Participation in September Investor Events". Jena....
- [2] InflaRx N.V.. (6/24/24). "Press Release: InflaRx’s Gohibic (vilobelimab) Selected for First BARDA-sponsored Clinical Trial to Evaluate Novel Host-directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)". Jena....
- [3] InflaRx N.V.. (2/22/24). "Press Release: InflaRx Appoints Jan Medina as Head of Investor Relations". Jena....
- [4] InflaRx N.V.. (1/25/24). "Press Release: InflaRx Announces Initiation of Its Commitment Program for GOHIBIC (vilobelimab) to Help Broaden Access for Eligible Patients". Ann Arbor, MI....
- [5] InflaRx N.V.. (4/18/23). "Press Release: InflaRx Announces Closing of the Full Exercise of Greenshoe Option Increasing the Proceeds of the Recently Announced Public Offering of Ordinary Shares to US$46 million". Jena....
- [6] InflaRx N.V.. (4/14/23). "Press Release: InflaRx Announces Closing of $40 Million Public Offering of Ordinary Shares". Jena....
- [7] InflaRx N.V.. (4/11/23). "Press Release: InflaRx Announces Public Offering of Ordinary Shares". Jena....
- [8] InflaRx N.V.. (4/11/23). "Press Release: InflaRx Announces Pricing of $40 Million Public Offering of Ordinary Shares". Jena....
- [9] InflaRx N.V.. (4/4/23). "Press Release: InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients". Jena....
- [10] InflaRx N.V.. (12/21/22). "Press Release: InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19". Jena....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top